NOVOLOG FLEXTOUCH (water injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
NOVOLOG FLEXTOUCH is a rapid-acting insulin analog (water injection) delivered via subcutaneous FlexTouch pen device, approved in 2000. It is indicated for COPD management, though this represents an atypical indication for an insulin product. The mechanism involves direct insulin analog activity to regulate glucose metabolism.
This product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a contracting commercial opportunity and likely smaller, maintenance-focused teams.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Investigation of the Analgesic Effects of Intradermal and Subdermal Sterile Water Injection on Active Labor Pain
Zero linked job openings indicate minimal active hiring for this product, reflecting its LOE status and mature commercial stage. Roles on this product focus on defending market share and managing transition rather than expansion and growth.
Worked on NOVOLOG FLEXTOUCH at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo